Valneva SE VLA-FR:

*Data is delayed
Last | EST
()
52 week range
-
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-

Key Stats

  • Market Cap1,119.17M
  • Shares Out107.73M
  • 10 Day Average Volume1.7M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-59.12

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-
  • Market Cap1,119.17M
  • Shares Out107.73M
  • 10 Day Average Volume1.7M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-59.12

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli...
Franck Grimaud
President, Chief Business Officer, Member of the Management Board
Perry Celentano
Interim Chief Operating Officer
Peter Buhler
Chief Financial Officer, Member of the Management Board
Gerald Strohmaier
Vice President of Human Resources, Member of the Executive Committee
Manfred Tiefenbacher
Vice President - Finance, Member of the Executive Committee
Address
6 rue Alain Bombard
Saint-herblain
44800
France